These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38937882)

  • 1. Disparities in Receipt of Adjuvant Immunotherapy among Stage III Melanoma Patients.
    Mulligan KM; Kakish H; Pawar O; Ahmed FA; Elshami M; Rothermel LD; Bordeaux JS; Sheng IY; Mangla A; Hoehn RS
    Am J Clin Oncol; 2024 Nov; 47(11):509-516. PubMed ID: 38937882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health care system and socioeconomic factors associated with variance in use of sentinel lymph node biopsy for melanoma in the United States.
    Bilimoria KY; Balch CM; Wayne JD; Chang DC; Palis BE; Dy SM; Lange JR
    J Clin Oncol; 2009 Apr; 27(11):1857-63. PubMed ID: 19273706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database.
    Dalle S; Varey E; Nguyen JM; Dupuy A; Montaudie H; Lesage C; Mortier L; Leccia MT; Skowron F; Celerier P; Meyer N; Dutriaux C; Dalac-Rat S; Khammari A; Lebbe C; Dréno B
    Eur J Dermatol; 2020 Aug; 30(4):389-396. PubMed ID: 32815816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
    Eggermont AM
    Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Completion lymph node dissection in patients with sentinel lymph node positive cutaneous head and neck melanoma.
    Huang K; Misra S; Lemini R; Chen Y; Speicher LL; Dawson NL; Tolaymat LM; Bagaria SP; Gabriel EM
    J Surg Oncol; 2020 Nov; 122(6):1057-1065. PubMed ID: 32654173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjusted Hospital Sentinel Lymph Node Positivity Rates in Melanoma: A Novel Potential Measure of Quality.
    Kinnier CV; Paruch JL; Dahlke AR; Wayne JD; Benson AB; Winchester DP; Bilimoria KY
    Ann Surg; 2016 Feb; 263(2):392-8. PubMed ID: 26488806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stage IIIa Melanoma and Impact of Multiple Positive Lymph Nodes on Survival.
    Woeste MR; McMasters KM; Egger ME
    J Am Coll Surg; 2021 Apr; 232(4):517-524.e1. PubMed ID: 33316426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis.
    Danish HH; Patel KR; Switchenko JM; Gillespie TW; Jhaveri J; Chowdhary M; Abugideiri M; Delman KA; Lawson DH; Khan MK
    Melanoma Res; 2016 Dec; 26(6):595-603. PubMed ID: 27575390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disparities in the Receipt of Systemic Treatment in Metastatic Melanoma.
    Kakish H; Pawar O; Bhatty M; Doh S; Mulligan KM; Rothermel LD; Bordeaux JS; Mangla A; Hoehn RS
    Am J Clin Oncol; 2024 May; 47(5):239-245. PubMed ID: 38251734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in the treatment and survival for local and regional cutaneous melanoma in a US population-based study.
    Harlan LC; Lynch CF; Ballard-Barbash R; Zeruto C
    Melanoma Res; 2011 Dec; 21(6):547-54. PubMed ID: 21897302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease.
    Anaya DA; Xing Y; Feng L; Huang X; Camacho LH; Ross MI; Gershenwald JE; Lee JE; Mansfield PF; Cormier JN
    Cancer; 2008 May; 112(9):2030-7. PubMed ID: 18320602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapies in the treatment of stage II and III malignant melanoma.
    Kavanagh D; Hill AD; Djikstra B; Kennelly R; McDermott EM; O'Higgins NJ
    Surgeon; 2005 Aug; 3(4):245-56. PubMed ID: 16121769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comorbidity burden on receipt of adjuvant immunotherapy and survival in patients with stage III melanoma: an analysis of the National Cancer Database.
    Freeman SC; Satish M; Walters RW
    Int J Dermatol; 2020 Nov; 59(11):1381-1390. PubMed ID: 32592609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk and Survival of Patients with Head and Neck Cutaneous Melanoma: National Perspective.
    Al-Qurayshi Z; Hassan M; Srivastav S; Sperry S; Pagedar N; Hamner J; Kandil E
    Oncology; 2017; 93(1):18-28. PubMed ID: 28423377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis.
    Broman KK; Hughes TM; Dossett LA; Sun J; Carr MJ; Kirichenko DA; Sharma A; Bartlett EK; Nijhuis AA; Thompson JF; Hieken TJ; Kottschade L; Downs J; Gyorki DE; Stahlie E; van Akkooi A; Ollila DW; Frank J; Song Y; Karakousis G; Moncrieff M; Nobes J; Vetto J; Han D; Farma J; Deneve JL; Fleming MD; Perez M; Baecher K; Lowe M; Bagge RO; Mattsson J; Lee AY; Berman RS; Chai H; Kroon HM; Teras RM; Teras J; Farrow NE; Beasley GM; Hui JY; Been L; Kruijff S; Boulware D; Sarnaik AA; Sondak VK; Zager JS;
    J Am Coll Surg; 2021 Apr; 232(4):424-431. PubMed ID: 33316427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sentinel lymph node biopsy in thick malignant melanoma: a 10-year single unit experience.
    Fairbairn NG; Orfaniotis G; Butterworth M
    J Plast Reconstr Aesthet Surg; 2012 Oct; 65(10):1396-402. PubMed ID: 22552263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study.
    Rapport F; Smith AL; Cust AE; Mann GJ; Watts CG; Gyorki DE; Henderson M; Hong AM; Kelly JW; Long GV; Mar VJ; Morton RL; Saw RP; Scolyer RA; Spillane AJ; Thompson JF; Braithwaite J
    BMJ Open; 2020 Feb; 10(2):e032636. PubMed ID: 32111612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial.
    Hoshimoto S; Shingai T; Morton DL; Kuo C; Faries MB; Chong K; Elashoff D; Wang HJ; Elashoff RM; Hoon DS
    J Clin Oncol; 2012 Nov; 30(31):3819-26. PubMed ID: 23008288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations.
    Verver D; van Klaveren D; van Akkooi ACJ; Rutkowski P; Powell BWEM; Robert C; Testori A; van Leeuwen BL; van der Veldt AAM; Keilholz U; Eggermont AMM; Verhoef C; Grünhagen DJ
    Eur J Cancer; 2018 Jun; 96():25-33. PubMed ID: 29660597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005).
    Chen AY; Halpern MT; Schrag NM; Stewart A; Leitch M; Ward E
    J Natl Cancer Inst; 2008 Apr; 100(7):462-74. PubMed ID: 18364506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.